SAN DIEGO, Jan. 21, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for oncology and rare diseases, today announced preliminary efficacy and safety data from the Phase...
Read More Details
Finally We wish PressBee provided you with enough information of ( Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer )
Also on site :
- ‘This is murder': Family remembers victims killed in Austin fire as 4th body recovered
- SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SGMA, NVEE, SOAR, PLL on Behalf of Shareholders
- Ilona Maher Gets Invite to Dance With Coco Gauff and Aryna Sabalenka